JAK-inhibition in Recurrent Classical Hodgkin Lymphoma
The Purpose of this trial is:

* to determine the overall response rate (ORR, complete response \[CR\] + partial response \[PR\]) in patients with relapsed or refractory HL
* to determine the safety profile of ruxolitinib in patients with relapsed or refractory HL
Recurrent Classical Hodgkin Lymphoma
DRUG: Ruxolitinib
overall response rate, 8 weeks
The Purpose of this trial is:

* to determine the overall response rate (ORR, complete response \[CR\] + partial response \[PR\]) in patients with relapsed or refractory HL
* to determine the safety profile of ruxolitinib in patients with relapsed or refractory HL